Formulating Antiviral Drug Combinations Using Spray Drying to Overcome Bioavailability Barriers

Kommanaboyana Srinivasa Rao

Research Scholar, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Tamil Nadu, India

K. Lakshmi ¹

Research Scholar, Chettinad School of Pharmaceutical Sciences, Chettinad Hospital and Research Institute (CHRI), Chettinad Academy of Research and Education (CARE), Kelambakkam, Tamil Nadu, India

Abstract

Lopinavir and ritonavir are co-administered antiretroviral agents widely used in the treatment of HIV-1 infection. Both are characterized by poor aqueous solubility and limited oral bioavailability, placing them within the Biopharmaceutics Classification System (BCS) Class II. While ritonavir serves primarily as a pharmacokinetic enhancer by inhibiting cytochrome P450 3A4 (CYP3A4), both compounds are susceptible to extensive first-pass metabolism and efflux via P-glycoprotein, necessitating advanced formulation strategies to ensure therapeutic efficacy. This research explores the development of a spray-dried amorphous solid dispersion (ASD) system to improve the solubility, dissolution rate, and bioavailability of lopinavir and ritonavir in a fixed-dose combination.

A series of spray-dried formulations were prepared using hydrophilic polymers, along with surfactants and stabilizers to enhance drug-polymer miscibility and prevent recrystallization. Physicochemical characterization was performed using differential scanning calorimetry (DSC), X-ray powder diffraction (XRPD), Fourier-transform infrared spectroscopy (FTIR), and scanning electron microscopy (SEM) to confirm the amorphous nature of the dispersions and evaluate molecular interactions. In vitro dissolution studies demonstrated a marked improvement in dissolution kinetics compared to crystalline and commercial forms.

Keywords

Lopinavir, Ritonavir, Spray drying, Solubility, Antiviral agents.